Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Director Sells $795,000.00 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Emma Reeve sold 10,000 shares of the firm’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $79.50, for a total value of $795,000.00. Following the completion of the sale, the director directly owned 6,666 shares of the company’s stock, valued at $529,947. This trade represents a 60.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Emma Reeve also recently made the following trade(s):

• On Wednesday, November 12th, Emma Reeve sold 7,333 shares of PTC Therapeutics stock. The shares were sold at an average price of $74.50, for a total transaction of $546,308.50.
• On Thursday, October 30th, Emma Reeve sold 15,666 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.50, for a total transaction of $1,088,787.00.
• On Friday, October 3rd, Emma Reeve sold 25,562 shares of PTC Therapeutics stock. The shares were sold at an average price of $65.96, for a total transaction of $1,686,069.52.
• On Thursday, September 11th, Emma Reeve sold 15,705 shares of PTC Therapeutics stock. The shares were sold at an average price of $59.50, for a total transaction of $934,447.50.

PTC Therapeutics Price Performance

Shares of NASDAQ PTCT opened at $86.25 on Friday. The company has a market capitalization of $6.92 billion, a P/E ratio of 12.37 and a beta of 0.60. The company has a 50 day simple moving average of $68.89 and a 200-day simple moving average of $56.65. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($1.19) by $1.39. The company had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.39) earnings per share. PTC Therapeutics has set its FY 2025 guidance at EPS. As a group, research analysts expect that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Institutional Investors Weigh In On PTC Therapeutics

Large investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its holdings in PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 236 shares in the last quarter. Optiver Holding B.V. increased its position in shares of PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 249 shares during the period. Comerica Bank increased its position in shares of PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 469 shares during the period. Quantbot Technologies LP raised its stake in shares of PTC Therapeutics by 545.5% in the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 551 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in PTC Therapeutics by 84.2% in the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 320 shares during the period.

Analyst Ratings Changes

A number of analysts recently issued reports on PTCT shares. Bank of America cut their price objective on PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating for the company in a research report on Wednesday, August 20th. Barclays increased their target price on shares of PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Royal Bank Of Canada boosted their price target on shares of PTC Therapeutics from $70.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Wells Fargo & Company boosted their target price on PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.40.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.